SEC Form 4 · accession 0001179110-17-013416
Syros Pharmaceuticals, Inc. · SYRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Colleen Elizabeth DeSimone
Officer — Principal Accounting Officer
Period of report
Oct 23, 2017
Accepted (ET)
Oct 23, 2017 · 4:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001556263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 23, 2017 | M | 550 | $3.04 | A | 550 | D | |
| Common StockF2 | Oct 23, 2017 | S | 550 | $16.0605 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $3.04 | Oct 23, 2017 | M | 550 | D | — | Jun 8, 2025 | Common Stock | 550 | 13,016 | D |
Explanation of responses
- F1The sale reported on this Form 4 was effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate exercise price within the range.
- F3This stock option was granted on June 9, 2015. It vested as to 25% of the underlying shares on April 27, 2016 and vests as the remaining shares in equal monthly installments on the last day of each month until April 27, 2019.